Annovis Bio Inc. announced on September 25, 2025, the appointment of Mark Guerin, CPA, CMA, CFM, as its new Chief Financial Officer (CFO). Mr. Guerin brings extensive experience and a successful track record in managing financial operations within biopharma companies. This appointment is intended to help lead the company through a pivotal phase of late-stage clinical development for buntanetap.
Mr. Guerin previously served as CFO at Onconova Therapeutics (now Traws Pharma, Inc.), where he managed financial reporting, forecasting, and internal controls following its IPO in 2013. During his tenure, Onconova completed several critical financing transactions, including rights offerings, public offerings, registered direct offerings, and at-the-market offerings. His experience includes facilitating post-acquisition integration activities and overseeing a New Drug Application filing.
Mark Guerin commented that he is excited to join Annovis at this critical juncture, as buntanetap has demonstrated efficacy in smaller trials and is on track to replicate that success in larger, registrational clinical studies. His expertise in financing and financial management is crucial for Annovis as it continues to fund its costly clinical development programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.